Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

Literature DB >> 24331294

EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

Abstract

Entities: Disease

Keywords: AE; ALT; BMI; BOC; BT; CPGs; CYP3A4; Clinical Practice Guidelines; DAA; DVR; EIA; EPO; EVR; G-CSF; GRADE; Grading of Recommendations Assessment, Development and Evaluation; HBV; HCC; HCV; IDU; IFN; IU; LSM; LT; OST; PI; PWID; PegIFN/RBV; RVR; SCAR; SVR; TSH; TVR; adverse event; alanine aminotransferase; boceprevir; body mass index; cytochrome p450 3A4; delayed virological response; direct-acting antiviral; eRVR; early virological response; enzyme immunoassays; erythropoietin; extended rapid virological response; granulocyte colony stimulating factor; hepatitis B virus; hepatitis C virus; hepatocellular carcinoma; interferon; international units; intravenous/injecting drug use; liver stiffness measurement; liver transplant; opiate/opioid substitution treatment/therapy; pegylated interferon-α and ribavirin; people who inject drugs; protease inhibitor; rapid virological response; severe cutaneous adverse reaction; sustained virological response; telaprevir; thyroid stimulating hormone; viral breakthrough

Mesh：

Substances：

Year: 2013 PMID： 24331294 DOI： 10.1016/j.jhep.2013.11.003

Source DB: PubMed Journal: J Hepatol ISSN： 0168-8278 Impact factor: 25.083

Keyword Cloud
Cited

× No keyword cloud information.

285 in total

1. Age-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infection.

Authors: Claudia Roeder; Sabine Jordan; Julian Schulze Zur Wiesch; Heike Pfeiffer-Vornkahl; Dietrich Hueppe; Stefan Mauss; Elmar Zehnter; Sabine Stoll; Ulrich Alshuth; Ansgar W Lohse; Stefan Lueth
Journal: World J Gastroenterol Date: 2014-08-21 Impact factor: 5.742

Review 2. Management of patients with hepatitis C infection and renal disease.

Authors: Chalermrat Bunchorntavakul; Monthira Maneerattanaporn; Disaya Chavalitdhamrong
Journal: World J Hepatol Date: 2015-02-27

3. 25-OH vitamin D level has no impact on the efficacy of antiviral therapy in naïve genotype 1 HCV-infected patients.

Authors: Arthur Belle; Emmanuel Gizard; Guillaume Conroy; Anthony Lopez; Magali Bouvier-Alias; Stéphanie Rouanet; Laurent Peyrin-Biroulet; Jean-Michel Pawlotsky; Jean-Pierre Bronowicki
Journal: United European Gastroenterol J Date: 2016-07-07 Impact factor: 4.623

4. Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients.

Authors: Luis Margusino-Framiñán; Purificación Cid-Silva; Sandra Rotea-Salvo; Álvaro Mena-de-Cea; Francisco Suárez-López; Pilar Vázquez-Rodríguez; Manuel Delgado-Blanco; Ana Isabel Sanclaudio-Luhia; Isabel Martín-Herranz; Ángeles Castro-Iglesias
Journal: Eur J Hosp Pharm Date: 2020-02-07

10. Impact of Hepatitis C Virus/Schistosoma mansoni Coinfection on the Circulating Levels of HCV-NS4 Protein and Extracellular-Matrix Deposition in Patients with Different Hepatic Fibrosis Stages.

Authors: Abdelfattah M Attallah; Sanaa O Abdallah; Mohamed S Albannan; Mohamed M Omran; Ahmed A Attallah; Khaled Farid
Journal: Am J Trop Med Hyg Date: 2016-08-15 Impact factor: 2.345

EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

1. Age-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infection.

Review 2. Management of patients with hepatitis C infection and renal disease.

3. 25-OH vitamin D level has no impact on the efficacy of antiviral therapy in naïve genotype 1 HCV-infected patients.

4. Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients.

5. Effectiveness and security of chronic hepatitis C treatment in coinfected patients in real-world.

Review 6. Enhancing our understanding of current therapies for hepatitis C virus (HCV).

Review 7. Management of hepatitis C infection before and after liver transplantation.

Review 8. Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade.

9. CD36 genetic variation, fat intake and liver fibrosis in chronic hepatitis C virus infection.

10. Impact of Hepatitis C Virus/Schistosoma mansoni Coinfection on the Circulating Levels of HCV-NS4 Protein and Extracellular-Matrix Deposition in Patients with Different Hepatic Fibrosis Stages.